SOPHIE GARDAN;DOMAIN THERAPEUTICS;KALDI PHARMA SAS;STANISLAS MAYER;STEPHAN SCHANN
发明人:
STEPHAN SCHANN,STANISLAS MAYER,SOPHIE GARDAN
申请号：
IL21416711
公开号：
IL214167A
申请日:
2011.07.19
申请国别(地区):
IL
年份:
2017
代理人:
摘要：
The present invention provides new compounds with high affinity for adenosine A 2A receptors. It also provides antagonists of adenosine A 2A receptors and their use as medicaments for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactivation of adenosine A 2A receptors signalling pathways could be beneficial such as Alzheimer's disease, Parkinson's disease, attention deficit and hyperactivity disorders (ADHD), Huntington's disease, neuroprotection, schizophrenia, anxiety and pain. The present invention further relates to pharmaceutical compositions containing such new compounds with high affinity for adenosine A 2A receptors and their use for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactivation of adenosine A 2A receptors could be beneficial.
